Not admitted · Vague or promotional

Part I of a series on the FDA advisory committee meeting of 2024-06-04, where the committee voted against MDMA-AT (Lykos Therapeutics) for PTSD. The author, who says he has PTSD himself and no stake in this modality winning, states his belief that MDMA, ibogaine, psilocybin and other psychedelic compounds will eventually deliver better treatments for PTSD than the current standard of care.

No entity, observable event, benchmark or threshold can be written from the text and its immediate context. Slogans ('game changer', 'once-in-a-lifetime opportunity', 'favourite stock') and quantifiers with no countable set ('more', 'first', 'all') without a defined set.